Imatinib
Product Images NDC 43598-344

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Imatinib (NDC 43598-344). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1

Packaging label for Imatinib Mesylate Tablets 100 mg by Dr.Reddy's Laboratories Inc. The label indicates the product is for institutional use only, with a quantity of 30 tablets (3 x 10 unit-dose). It includes storage instructions, usage warnings, and barcodes. Distributor information for Dr.Reddy's Laboratories Inc., Princeton NJ, USA is also present.*

FDA Label Image

Carton2

Imatinib Mesylate Tablets 400 mg carton label for institutional use only, containing 30 tablets (3 x 10 unit-dose). The label shows the drug name, strength, dosage form, and quantity, with instructions for storage and usage. The product is labeled as Rx only and distributed by Dr. Reddy's Laboratories Inc.*

FDA Label Image

Container1 (Container1)

Label for Imatinib Mesylate Tablets 100 mg by Dr. Reddy's Laboratories Inc. The label indicates the product contains 90 film-coated tablets, includes usage storage instructions, distributor information, a barcode, and an NDC number 43598-344-90. It specifies the product is made in India and provides handling precautions.*

FDA Label Image

Container2 (Container2)

Text panel for Imatinib Mesylate Tablets 400 mg from Dr. Reddy's Laboratories Inc. It includes dosage information, storage instructions, a caution to keep out of reach of children, and distributor details. The panel also shows the NDC number 43598-345-30 and package count of 30 tablets.*

FDA Label Image

Figure1 (Figure1)

A Kaplan-Meier survival curve chart displaying the percentage of patients without progression over time in months since randomization. It compares two treatment arms: Imatinib Mesylate and IFN+Ara-C, including the number of patients, hazard ratio with 95% confidence interval, and a log-rank test p-value. The chart shows higher percentages without progression in the Imatinib Mesylate arm over the follow-up period.*

FDA Label Image

Figure2 (Figure2)

A survival curve chart comparing the percentage without progression to AP or BC between Imatinib Mesylate and IFN+Ara-C treatment arms over months since randomization, including patient numbers, hazard ratio, confidence interval, and statistical significance.*

FDA Label Image

Structure (Structure)

Chemical structure of Imatinib, showing the molecular arrangement and bonding of atoms including nitrogen, carbon, hydrogen, and sulfur as part of its mesylate form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.